OTLK - NASDAQ
Outlook Therapeutics, Inc.
$1.58
-0.94%Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
At a Glance
Live SnapshotOutlook Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Thin margins leave little room for error. Cost management and pricing strategy are critical.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Outlook Therapeutics, Inc. Income Statement
OTLK • NASDAQ
| Outlook Therapeutics, Inc. Income Statement | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||
1,413.5B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.1M | 3.1M | 3.8M | 3M | 5.2M | 9.1M | |
GROSS PROFIT | ||||||||||||
(1,356.3B) | (113.9K) | (44.2K) | (204.7K) | (262.1K) | (554.1K) | (23.8M) | (18.5M) | (23.8M) | (0.0) | (0.0) | (0.0) | |
57.2B | -113.9K | -44.2K | -204.7K | -262.1K | -554.1K | -15.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||||
(67,118.9B) | (71.7M) | (53.1M) | (62.9M) | (51.7M) | (34.4M) | (44.4M) | (32.7M) | (39.7M) | (21.6M) | (51.8M) | (21.4M) | |
(39,938.2B) | (29.9M) | (26.7M) | (20.7M) | (12.8M) | (10M) | (9.4M) | (14.2M) | (15.9M) | (21.6M) | (12.9M) | (7.3M) | |
(27,180.6B) | (41.8M) | (26.5M) | (42.3M) | (39M) | (26.3M) | (23.8M) | (18.5M) | (23.8M) | (32.8M) | (38.9M) | (14.1M) | |
-67,061.7B | -71.7M | -53.1M | -63.1M | -51.7M | -36.8M | -36.3M | -29.6M | -35.9M | -51.3M | -46.6M | -12.4M | |
PRE-TAX INCOME | ||||||||||||
(283.1B) | (3.2M) | (1.6M) | (1.5M) | (936.1K) | (1.8M) | (3.5M) | (3.9M) | (5.6M) | (1.9M) | (2.3M) | (901.1K) | |
0.0 | -2.3M | -1.6M | -1.5M | -936.1K | -1.8M | -3.5M | -3.9M | -5.6M | -1.9M | -2.3M | -901K | |
(0.0) | (0.0) | (0.0) | -205K | (0.0) | -1.9M | (11.3M) | (0.0) | -23.8M | (0.0) | (0.0) | (0.0) | |
3,085B | -3.7M | -5.9M | -3M | -1.4M | -1.7M | -1.6M | -4.1M | -2.5M | -1.9M | -2.3M | -901K | |
-63,976.7B | -75.4M | -59M | -66M | -53.2M | -38.5M | -37.9M | -33.7M | -38.3M | -53.2M | -48.9M | -13.3M | |
NET INCOME | ||||||||||||
-1,551.8B | (2.8K) | (2.8K) | (2.8K) | (2K) | -3.3M | -3.4M | -3.6M | (501.5K) | (103K) | -190K | (439K) | |
-62,424.9B | -75.4M | -59M | -66.1M | -53.2M | -35.2M | -34.5M | -30.1M | -38.8M | -53.3M | -47.4M | -13.7M |
SEC Filings
OTLK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-K 10-K 2025 FY FY | December 19, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 19, 2025 | December 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 29, 2025 | September 29, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 05, 2025 | September 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 02, 2025 | August 28, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 14, 2025 | August 14, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 14, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 01, 2025 | June 28, 2025 | 2025 |
Related Guides
Continue your OTLK research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.